Perkinelmer (PKI) 55.53 $PKI PerkinElmer to Pre
Post# of 273254
Posted On: 09/24/2016 3:14:36 PM
Perkinelmer (PKI) 55.53 $PKI
PerkinElmer to Present at Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Sep 01, 3:15PM CDT
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 11:40am ET at the Grand Hyatt Hotel in New York City.
PKI: 55.53 (-0.08), MS: 31.91 (-0.33)
PerkinElmer Webinar Spotlights Advanced Analysis of Complex Cell Models with New High-Content Analysis System
PRWeb - Mon Aug 29, 4:02PM CDT
In line with a growing trend, scientists are developing in vitro cell models that repeat the in vivo environment in basic research, developmental biology, drug discovery, and toxicology. In an effort to form 3D structures or scaffolds to produce detailed phenotypic fingerprints for enhanced biological insights in live-cell and fixed-endpoint assays, scientists are using more complex cellular models, such as ex vivo tissue, primary cells, stem cells, or a combination of co-culture cells.
PKI: 55.53 (-0.08)
Research Report Initiation on These Healthcare Stocks -- VWR Corp., DexCom, Laboratory Corp. of America, and PerkinElmer
PR Newswire - Thu Aug 25, 7:00AM CDT
Operators in the Medical Laboratories and Research segment provide healthcare practitioners with information concerning the onset, severity, and cause of patients' ailments and illnesses. Equities under evaluation on Stock-Callers.com are: VWR Corp. (NASDAQ: VWR), DexCom Inc. (NASDAQ: DXCM), Laboratory Corp. of America Holdings (NYSE: LH), and PerkinElmer Inc. (NYSE: PKI). Learn more about these stocks by downloading their free report at:
DXCM: 93.91 (-0.11), VWR: 28.43 (+0.09), LH: 137.39 (-0.44), PKI: 55.53 (-0.08)
Fitch Rates PerkinElmer's New Revolver 'BBB'; Outlook Stable
BusinessWire - Tue Aug 16, 10:11AM CDT
Fitch Ratings has assigned a 'BBB' rating to PerkinElmer Inc.'s (PerkinElmer) new $1 billion unsecured revolving credit facility (RCF) that matures Aug. 11, 2021. The new facility replaces PerkinElmer's previous $700 million unsecured RCF that was scheduled to mature in January 2019. The Rating Outlook is Stable.
PKI: 55.53 (-0.08)
Global Microscope Accessories Market 2016-2020 with Bruker, Carl Zeiss, Leica Microsystems, PerkinElmer & Thermo Fisher Scientific Dominating - Research and Markets
BusinessWire - Tue Aug 16, 6:21AM CDT
Research and Markets has announced the addition of the "Global Microscope Accessories Market 2016-2020" report to their offering.
PKI: 55.53 (-0.08)
PerkinElmer Webinar Highlights Emerging Applications in Preclinical MicroCT Imaging
PRWeb - Thu Aug 11, 4:36PM CDT
Preclinical micro-computed tomography (microCT) imaging systems, which provide higher-quality spatial resolution than many other imaging modalities, are optimal for a vast range of applications that demand imaging of small anatomical structures, such as vessels and bones. Our overall understanding of disease has increased, thanks in part to recent research that incorporates microCT data with optical and nuclear data to generate multimodality datasets. The Quantum GX microCT imaging system from PerkinElmer offers high-resolution scanning, high-throughput scan times, and accommodates imaging protocols with radiation doses low enough to facilitate longitudinal studies. MicroCT imaging is enabling many emerging applications and its features inform on functional and anatomical information.
PKI: 55.53 (-0.08)
PerkinElmer (PKI) Beats Q2 Earnings, FY16 View Maintained
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:32PM CDT
PerkinElmer Inc (PKI) reported second-quarter 2016 earnings of 67 cents per share, which beat the Zacks Consensus Estimate by a penny.
HYH: 33.96 (-0.92), MASI: 59.77 (-0.55), PKI: 55.53 (-0.08), MMSI: 23.96 (-0.32)
PerkinElmer Announces Financial Results for the Second Quarter of 2016
BusinessWire - Thu Aug 04, 3:15PM CDT
--GAAP earnings per share from continuing operations of $0.56; Adjusted earnings per share of $0.67
PKI: 55.53 (-0.08)
Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 66.64 (-0.17), GLYC: 7.20 (-0.09), PKI: 55.53 (-0.08), HUM: 175.55 (-0.44)
PerkinElmer Elects Frank Witney to Board of Directors
BusinessWire - Wed Jul 27, 3:15PM CDT
PerkinElmer, Inc. (NYSE
KI), a global leader focused on improving the health and safety of people and the environment, today announced that Frank Witney, Ph.D., has been elected to the Company's Board of Directors.
PKI: 55.53 (-0.08)
PerkinElmer Board Declares Quarterly Dividend
BusinessWire - Wed Jul 27, 3:15PM CDT
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on July 27, 2016. This dividend is payable on November 10, 2016 to all shareholders of record at the close of business on October 14, 2016.
PKI: 55.53 (-0.08)
Top Stocks with Big Potential Catch-Up Moves
Kevin Matras - ZACKS - Tue Jul 26, 2:31PM CDT
Top Stocks with Big Potential Catch-Up Moves
CSGP: 218.00 (-0.64), CW: 88.40 (-0.97), INGN: 61.04 (+0.25), HLS: 40.89 (-0.37), PKI: 55.53 (-0.08)
Gyros Protein Technologies Appoints Frank Witney as Chairman
BusinessWire - Wed Jun 22, 8:47AM CDT
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the appointment of Dr. Frank Witney as Chairman of the Board. Dr. Witney's appointment is a key milestone in Gyros Protein Technologies' strategy to build upon the Company's strong market position through ongoing development of innovative products, commercial expansion, and growth via acquisition. David Patteson, prior chairman of Protein Technologies, Inc. remains as a Director.
PKI: 55.53 (-0.08)
PerkinElmer, Inc. (PKI) - Product Pipeline Market Analysis Report by Radiant Insights
GlobeNewswire - Wed Jun 22, 6:39AM CDT
PerkinElmer, Inc. (PerkinElmer) is a provider of detection, imaging, and informatics solutions and services to diagnostics, research, laboratory services, environmental, and industrial markets. The company's product portfolio comprises lab products and services; imaging components; diagnostic services for clinicians and families; and cord blood and tissue banking services. It also offers technologies for detection and identification of disease, contaminants, and biological pathways; imaging technologies for recording biological, cellular, and treatment events; and software platforms and informatics for data management, visualization, analytics, efficient workflow. PerkinElmer's products find applications in early detection of genetic disorders, infectious disease testing, diagnosis of metabolic disorders, cancer treatment, drug discovery and other research activities. Its service offerings include analytics, compliance, contract research, custom research, genetic screening, instrumentation, prenatal screening, information, and scientific services.
PKI: 55.53 (-0.08)
NuGEN Technologies Appoints New CEO
BusinessWire - Tue Jun 14, 5:00AM CDT
NuGEN Technologies, Inc. today announced the appointment of Nitin Sood as Chief Executive Officer. He succeeds Elizabeth Hutt who recently left to pursue another opportunity.
PKI: 55.53 (-0.08)
PerkinElmer and Sofie Biosciences extend and expand partnership
PR Newswire - Fri Jun 10, 3:00PM CDT
SOFIE BIOSCIENCES, a molecular imaging company, and PerkinElmer, a global leader in the life sciences, are pleased to announce a multi-year extension of their existing partnership to deliver preclinical in vivo imaging tools for positron emission tomography (PET). PET is a non-invasive, translational imaging technology that quantitatively and safely measures the biology of disease.
PKI: 55.53 (-0.08)
Premarket Research Report Covering the Medical Laboratories & Research Industry
ACCESSWIRE - Thu Jun 09, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 9, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Laboratories & Research industry. Companies recently under review include Thermo Fisher Scientific, Great Basin Scientific, PerkinElmer, and Organovo. Register with us now for your free membership and see our complete reports on these equities at:
GBSN: 2.95 (-0.02), TMO: 157.66 (unch), ONVO: 3.97 (-0.03), PKI: 55.53 (-0.08)
PerkinElmer Webinar on Rethinking Timeline for Quality by Design Studies in Protein Process Development
PRWeb - Wed Jun 01, 2:21PM CDT
A perpetual challenge is posed by improving systems for rapid small-scale protein purification and analysis used to acquire sample numbers for statistically significant analyses needed for the selection of lead candidate molecules.
PKI: 55.53 (-0.08)
PerkinElmer Opens Customer Knowledge Center in Taiwan
BusinessWire - Fri May 27, 12:00AM CDT
PerkinElmer, Inc. held an opening ceremony for its new Taipei Customer Knowledge Center (CKC) located in Neihu District, Taipei City on May 27. President of PerkinElmer's Environmental Health business, Jon DiVincenzo, as well as Vice President and General Manager of Global Sales and Service, Nam-Hoon Kim, hosted more than 70 guests from the environmental, chemicals and semiconductor testing industries and academia, along with PerkinElmer representatives from the Asia-Pacific region.
PKI: 55.53 (-0.08)
Waters Corp. Expands Xevo Line with Xevo TQ-XS Launch
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:44AM CDT
Waters Corporation (WAT) expanded its portfolio of Xevo mass spectrometers with the launch of Xevo TQ-XS mass spectrometer, which is arguably the most sensitive instrument of its kind in the market.
BEAT: 18.72 (+0.12), BRKR: 22.37 (-0.18), PKI: 55.53 (-0.08), WAT: 157.67 (-0.15)
PerkinElmer to Present at Morgan Stanley Global Healthcare Conference
BusinessWire - Thu Sep 01, 3:15PM CDT
PerkinElmer, Inc. (NYSE: PKI), a global leader focused on improving the health and safety of people and the environment, today announced that the Company will present at the Morgan Stanley Global Healthcare Conference on Monday, September 12, 2016 at 11:40am ET at the Grand Hyatt Hotel in New York City.
PKI: 55.53 (-0.08), MS: 31.91 (-0.33)
PerkinElmer Webinar Spotlights Advanced Analysis of Complex Cell Models with New High-Content Analysis System
PRWeb - Mon Aug 29, 4:02PM CDT
In line with a growing trend, scientists are developing in vitro cell models that repeat the in vivo environment in basic research, developmental biology, drug discovery, and toxicology. In an effort to form 3D structures or scaffolds to produce detailed phenotypic fingerprints for enhanced biological insights in live-cell and fixed-endpoint assays, scientists are using more complex cellular models, such as ex vivo tissue, primary cells, stem cells, or a combination of co-culture cells.
PKI: 55.53 (-0.08)
Research Report Initiation on These Healthcare Stocks -- VWR Corp., DexCom, Laboratory Corp. of America, and PerkinElmer
PR Newswire - Thu Aug 25, 7:00AM CDT
Operators in the Medical Laboratories and Research segment provide healthcare practitioners with information concerning the onset, severity, and cause of patients' ailments and illnesses. Equities under evaluation on Stock-Callers.com are: VWR Corp. (NASDAQ: VWR), DexCom Inc. (NASDAQ: DXCM), Laboratory Corp. of America Holdings (NYSE: LH), and PerkinElmer Inc. (NYSE: PKI). Learn more about these stocks by downloading their free report at:
DXCM: 93.91 (-0.11), VWR: 28.43 (+0.09), LH: 137.39 (-0.44), PKI: 55.53 (-0.08)
Fitch Rates PerkinElmer's New Revolver 'BBB'; Outlook Stable
BusinessWire - Tue Aug 16, 10:11AM CDT
Fitch Ratings has assigned a 'BBB' rating to PerkinElmer Inc.'s (PerkinElmer) new $1 billion unsecured revolving credit facility (RCF) that matures Aug. 11, 2021. The new facility replaces PerkinElmer's previous $700 million unsecured RCF that was scheduled to mature in January 2019. The Rating Outlook is Stable.
PKI: 55.53 (-0.08)
Global Microscope Accessories Market 2016-2020 with Bruker, Carl Zeiss, Leica Microsystems, PerkinElmer & Thermo Fisher Scientific Dominating - Research and Markets
BusinessWire - Tue Aug 16, 6:21AM CDT
Research and Markets has announced the addition of the "Global Microscope Accessories Market 2016-2020" report to their offering.
PKI: 55.53 (-0.08)
PerkinElmer Webinar Highlights Emerging Applications in Preclinical MicroCT Imaging
PRWeb - Thu Aug 11, 4:36PM CDT
Preclinical micro-computed tomography (microCT) imaging systems, which provide higher-quality spatial resolution than many other imaging modalities, are optimal for a vast range of applications that demand imaging of small anatomical structures, such as vessels and bones. Our overall understanding of disease has increased, thanks in part to recent research that incorporates microCT data with optical and nuclear data to generate multimodality datasets. The Quantum GX microCT imaging system from PerkinElmer offers high-resolution scanning, high-throughput scan times, and accommodates imaging protocols with radiation doses low enough to facilitate longitudinal studies. MicroCT imaging is enabling many emerging applications and its features inform on functional and anatomical information.
PKI: 55.53 (-0.08)
PerkinElmer (PKI) Beats Q2 Earnings, FY16 View Maintained
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 2:32PM CDT
PerkinElmer Inc (PKI) reported second-quarter 2016 earnings of 67 cents per share, which beat the Zacks Consensus Estimate by a penny.
HYH: 33.96 (-0.92), MASI: 59.77 (-0.55), PKI: 55.53 (-0.08), MMSI: 23.96 (-0.32)
PerkinElmer Announces Financial Results for the Second Quarter of 2016
BusinessWire - Thu Aug 04, 3:15PM CDT
--GAAP earnings per share from continuing operations of $0.56; Adjusted earnings per share of $0.67
PKI: 55.53 (-0.08)
Can PerkinElmer (PKI) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:24AM CDT
PerkinElmer Inc. is expected to report second-quarter 2016 results on Aug 4.
ANIP: 66.64 (-0.17), GLYC: 7.20 (-0.09), PKI: 55.53 (-0.08), HUM: 175.55 (-0.44)
PerkinElmer Elects Frank Witney to Board of Directors
BusinessWire - Wed Jul 27, 3:15PM CDT
PerkinElmer, Inc. (NYSE
KI), a global leader focused on improving the health and safety of people and the environment, today announced that Frank Witney, Ph.D., has been elected to the Company's Board of Directors. PKI: 55.53 (-0.08)
PerkinElmer Board Declares Quarterly Dividend
BusinessWire - Wed Jul 27, 3:15PM CDT
The Board of Directors of PerkinElmer, Inc. (NYSE: PKI), declared a regular quarterly dividend of $0.07 per share of common stock on July 27, 2016. This dividend is payable on November 10, 2016 to all shareholders of record at the close of business on October 14, 2016.
PKI: 55.53 (-0.08)
Top Stocks with Big Potential Catch-Up Moves
Kevin Matras - ZACKS - Tue Jul 26, 2:31PM CDT
Top Stocks with Big Potential Catch-Up Moves
CSGP: 218.00 (-0.64), CW: 88.40 (-0.97), INGN: 61.04 (+0.25), HLS: 40.89 (-0.37), PKI: 55.53 (-0.08)
Gyros Protein Technologies Appoints Frank Witney as Chairman
BusinessWire - Wed Jun 22, 8:47AM CDT
Gyros Protein Technologies AB, a pioneer in automated nanoliter-scale immunoassays and leading provider of peptide synthesizers and reagents, today announced the appointment of Dr. Frank Witney as Chairman of the Board. Dr. Witney's appointment is a key milestone in Gyros Protein Technologies' strategy to build upon the Company's strong market position through ongoing development of innovative products, commercial expansion, and growth via acquisition. David Patteson, prior chairman of Protein Technologies, Inc. remains as a Director.
PKI: 55.53 (-0.08)
PerkinElmer, Inc. (PKI) - Product Pipeline Market Analysis Report by Radiant Insights
GlobeNewswire - Wed Jun 22, 6:39AM CDT
PerkinElmer, Inc. (PerkinElmer) is a provider of detection, imaging, and informatics solutions and services to diagnostics, research, laboratory services, environmental, and industrial markets. The company's product portfolio comprises lab products and services; imaging components; diagnostic services for clinicians and families; and cord blood and tissue banking services. It also offers technologies for detection and identification of disease, contaminants, and biological pathways; imaging technologies for recording biological, cellular, and treatment events; and software platforms and informatics for data management, visualization, analytics, efficient workflow. PerkinElmer's products find applications in early detection of genetic disorders, infectious disease testing, diagnosis of metabolic disorders, cancer treatment, drug discovery and other research activities. Its service offerings include analytics, compliance, contract research, custom research, genetic screening, instrumentation, prenatal screening, information, and scientific services.
PKI: 55.53 (-0.08)
NuGEN Technologies Appoints New CEO
BusinessWire - Tue Jun 14, 5:00AM CDT
NuGEN Technologies, Inc. today announced the appointment of Nitin Sood as Chief Executive Officer. He succeeds Elizabeth Hutt who recently left to pursue another opportunity.
PKI: 55.53 (-0.08)
PerkinElmer and Sofie Biosciences extend and expand partnership
PR Newswire - Fri Jun 10, 3:00PM CDT
SOFIE BIOSCIENCES, a molecular imaging company, and PerkinElmer, a global leader in the life sciences, are pleased to announce a multi-year extension of their existing partnership to deliver preclinical in vivo imaging tools for positron emission tomography (PET). PET is a non-invasive, translational imaging technology that quantitatively and safely measures the biology of disease.
PKI: 55.53 (-0.08)
Premarket Research Report Covering the Medical Laboratories & Research Industry
ACCESSWIRE - Thu Jun 09, 8:17AM CDT
LONDON, UK / ACCESSWIRE / June 9, 2016 / ActiveWallSt.com announces the list of stocks for today's research coverage. Pre-market the Active Wall St. team provides the latest corporate, market and technical events impacting selected stocks on the Medical Laboratories & Research industry. Companies recently under review include Thermo Fisher Scientific, Great Basin Scientific, PerkinElmer, and Organovo. Register with us now for your free membership and see our complete reports on these equities at:
GBSN: 2.95 (-0.02), TMO: 157.66 (unch), ONVO: 3.97 (-0.03), PKI: 55.53 (-0.08)
PerkinElmer Webinar on Rethinking Timeline for Quality by Design Studies in Protein Process Development
PRWeb - Wed Jun 01, 2:21PM CDT
A perpetual challenge is posed by improving systems for rapid small-scale protein purification and analysis used to acquire sample numbers for statistically significant analyses needed for the selection of lead candidate molecules.
PKI: 55.53 (-0.08)
PerkinElmer Opens Customer Knowledge Center in Taiwan
BusinessWire - Fri May 27, 12:00AM CDT
PerkinElmer, Inc. held an opening ceremony for its new Taipei Customer Knowledge Center (CKC) located in Neihu District, Taipei City on May 27. President of PerkinElmer's Environmental Health business, Jon DiVincenzo, as well as Vice President and General Manager of Global Sales and Service, Nam-Hoon Kim, hosted more than 70 guests from the environmental, chemicals and semiconductor testing industries and academia, along with PerkinElmer representatives from the Asia-Pacific region.
PKI: 55.53 (-0.08)
Waters Corp. Expands Xevo Line with Xevo TQ-XS Launch
Zacks Equity Research - Zacks Investment Research - Tue May 17, 8:44AM CDT
Waters Corporation (WAT) expanded its portfolio of Xevo mass spectrometers with the launch of Xevo TQ-XS mass spectrometer, which is arguably the most sensitive instrument of its kind in the market.
BEAT: 18.72 (+0.12), BRKR: 22.37 (-0.18), PKI: 55.53 (-0.08), WAT: 157.67 (-0.15)
(0)
(0)Scroll down for more posts ▼